[go: up one dir, main page]

AT500379A3 - Tau-proteine - Google Patents

Tau-proteine Download PDF

Info

Publication number
AT500379A3
AT500379A3 AT0017501A AT1752001A AT500379A3 AT 500379 A3 AT500379 A3 AT 500379A3 AT 0017501 A AT0017501 A AT 0017501A AT 1752001 A AT1752001 A AT 1752001A AT 500379 A3 AT500379 A3 AT 500379A3
Authority
AT
Austria
Prior art keywords
tau
tau proteins
normal
proteins
conformationally different
Prior art date
Application number
AT0017501A
Other languages
English (en)
Other versions
AT500379B1 (de
AT500379B8 (de
AT500379A2 (de
Original Assignee
Axon Neuroscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0017501A priority Critical patent/AT500379B8/de
Application filed by Axon Neuroscience filed Critical Axon Neuroscience
Priority to PCT/EP2002/000897 priority patent/WO2002062851A1/en
Priority to DK02703586.4T priority patent/DK1355949T3/da
Priority to CNB028053133A priority patent/CN100503638C/zh
Priority to EP02703586A priority patent/EP1355949B1/de
Priority to DE60235746T priority patent/DE60235746D1/de
Priority to ES02703586T priority patent/ES2339427T3/es
Priority to CA2437453A priority patent/CA2437453C/en
Priority to RU2003126594/13A priority patent/RU2299889C2/ru
Priority to AU2002237296A priority patent/AU2002237296A1/en
Priority to CNA2008101081547A priority patent/CN101307107A/zh
Priority to AT02703586T priority patent/ATE461941T1/de
Priority to JP2002563203A priority patent/JP4163955B2/ja
Priority to US10/470,928 priority patent/US7446180B2/en
Publication of AT500379A2 publication Critical patent/AT500379A2/de
Priority to US12/264,694 priority patent/US20090123936A1/en
Publication of AT500379A3 publication Critical patent/AT500379A3/de
Publication of AT500379B1 publication Critical patent/AT500379B1/de
Application granted granted Critical
Publication of AT500379B8 publication Critical patent/AT500379B8/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT0017501A 2001-02-02 2001-02-02 Tau-proteine AT500379B8 (de)

Priority Applications (15)

Application Number Priority Date Filing Date Title
AT0017501A AT500379B8 (de) 2001-02-02 2001-02-02 Tau-proteine
CNA2008101081547A CN101307107A (zh) 2001-02-02 2002-01-29 tau蛋白
CNB028053133A CN100503638C (zh) 2001-02-02 2002-01-29 tau蛋白
EP02703586A EP1355949B1 (de) 2001-02-02 2002-01-29 Antikörper gegen Alzheimer spezifische tau Proteine mit abnormaler Konformation
DE60235746T DE60235746D1 (de) 2001-02-02 2002-01-29 Antikörper gegen Alzheimer spezifische tau Proteine mit abnormaler Konformation
ES02703586T ES2339427T3 (es) 2001-02-02 2002-01-29 Anticuerpos contra formas conformacionalmente anormales de proteina tau presente en tejidos con enfermedad de alzheimer.
CA2437453A CA2437453C (en) 2001-02-02 2002-01-29 Conformationally abnormal forms of tau proteins and specific antibodies thereto
RU2003126594/13A RU2299889C2 (ru) 2001-02-02 2002-01-29 Конформационно аномальные формы белков тау и специфические антитела к ним
PCT/EP2002/000897 WO2002062851A1 (en) 2001-02-02 2002-01-29 Conformationally abnormal forms of tau proteins and specific antibodies thereto
DK02703586.4T DK1355949T3 (da) 2001-02-02 2002-01-29 Antistoffer mod konformationelt abnorme former af tau-protein der forekommer i væv ved Alzheimers sygdom
AT02703586T ATE461941T1 (de) 2001-02-02 2002-01-29 Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation
JP2002563203A JP4163955B2 (ja) 2001-02-02 2002-01-29 構造的に異常な形のタウタンパク質およびそれに対する特異抗体
US10/470,928 US7446180B2 (en) 2001-02-02 2002-01-29 Conformationally abnormal forms of tau proteins and specific antibodies thereto
AU2002237296A AU2002237296A1 (en) 2001-02-02 2002-01-29 Conformationally abnormal forms of tau proteins and specific antibodies thereto
US12/264,694 US20090123936A1 (en) 2001-02-02 2008-11-04 Conformationally abnormal forms of tau proteins and specific antibodies thereto

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0017501A AT500379B8 (de) 2001-02-02 2001-02-02 Tau-proteine

Publications (4)

Publication Number Publication Date
AT500379A2 AT500379A2 (de) 2005-12-15
AT500379A3 true AT500379A3 (de) 2009-02-15
AT500379B1 AT500379B1 (de) 2009-07-15
AT500379B8 AT500379B8 (de) 2009-08-15

Family

ID=3658236

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0017501A AT500379B8 (de) 2001-02-02 2001-02-02 Tau-proteine
AT02703586T ATE461941T1 (de) 2001-02-02 2002-01-29 Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02703586T ATE461941T1 (de) 2001-02-02 2002-01-29 Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation

Country Status (12)

Country Link
US (2) US7446180B2 (de)
EP (1) EP1355949B1 (de)
JP (1) JP4163955B2 (de)
CN (2) CN101307107A (de)
AT (2) AT500379B8 (de)
AU (1) AU2002237296A1 (de)
CA (1) CA2437453C (de)
DE (1) DE60235746D1 (de)
DK (1) DK1355949T3 (de)
ES (1) ES2339427T3 (de)
RU (1) RU2299889C2 (de)
WO (1) WO2002062851A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
DK1521831T3 (da) * 2002-07-12 2008-06-30 Axon Neuroscience Transgent dyr der udtrykker trunkeret alzheimers tauprotein
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
ES2453941T5 (es) 2005-11-30 2017-05-31 Abbvie Inc. Anticuerpos monoclonales contra la proteína beta amiloide y usos de los mismos
ES2321996B1 (es) * 2006-01-26 2010-03-05 Consejo Superior Investig. Cientificas Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias.
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2009143556A1 (en) * 2008-05-30 2009-12-03 The University Of Sydney TREATMENTS FOR EXCITOTOXICITY AND Aß-MEDIATED TOXICITY AND AGE-ASSOCIATED NEURONAL DYSFUNCTION
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA2765099A1 (en) * 2009-06-10 2010-12-16 New York University Phosphorylated tau peptide for use in the treatment of tauopathy
JP6124591B2 (ja) * 2009-08-28 2017-05-10 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム タウオリゴマーに結合する抗体
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
ITRM20100320A1 (it) 2010-06-11 2011-12-11 Consiglio Nazionale Ricerche Metodo per la diagnostica e il trattamento delle taupatie
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
BR112013008765B8 (pt) 2010-10-11 2023-05-02 Biogen Idec Int Neuroscience Gmbh Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
CA2817973C (en) 2010-10-15 2019-06-25 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
EP2709728B1 (de) * 2011-05-20 2019-01-23 Oligomerix, Inc. Tau-protease-anwendungsverfahren
SG10201912955PA (en) 2011-09-19 2020-02-27 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
CN108034005B (zh) * 2011-10-07 2021-06-25 Ac免疫有限公司 识别Tau的磷酸化特异抗体
KR20200013072A (ko) 2012-07-03 2020-02-05 워싱턴 유니버시티 Tau에 대한 항체
NZ630542A (en) * 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
US9200068B2 (en) * 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
BR112015014751A8 (pt) 2012-12-21 2018-01-16 Biogen Int Neuroscience Gmbh anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
JP6568514B2 (ja) * 2013-03-15 2019-08-28 エーシー イミューン エス．エー． 抗タウ抗体及び使用方法
PE20161032A1 (es) 2013-12-20 2016-10-19 Hoffmann La Roche Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
WO2015122922A1 (en) 2014-02-14 2015-08-20 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TW202136296A (zh) * 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
US10132818B2 (en) 2014-07-08 2018-11-20 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
JP6793134B2 (ja) * 2015-06-05 2020-12-02 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
ES2809728T3 (es) * 2015-06-24 2021-03-05 Hoffmann La Roche Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
MX2017015817A (es) 2015-07-06 2018-04-10 Ucb Biopharma Sprl Anticuerpos de union a tau.
US10988528B2 (en) 2015-08-13 2021-04-27 New York University Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
JP7170316B2 (ja) 2016-05-02 2022-11-14 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
EP3452508A1 (de) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antikörper zur erkennung von tau
MY197836A (en) * 2016-07-12 2023-07-20 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
WO2018031361A2 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
MA48595A (fr) 2016-12-07 2020-03-18 Ac Immune Sa Anticorps anti-tau et leurs méthodes d'utilisation
KR20240035636A (ko) 2016-12-07 2024-03-15 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
CA3061516A1 (en) 2017-05-02 2018-11-08 Prothena Biosciences Limited Antibodies recognizing tau
EP3658172A4 (de) 2017-07-25 2021-05-05 TrueBinding, Inc. Behandlung von krebs durch blockierung der interaktion von tim-3 und seinem liganden
CN107686839B (zh) * 2017-09-25 2020-12-04 安徽朵能生物科技有限公司 微管结合蛋白cript、其治疗性突变体及其应用
EP3829634A1 (de) 2018-07-31 2021-06-09 Eli Lilly and Company Kombinationstherapie
BR112021016947A2 (pt) 2019-03-03 2021-11-03 Prothena Biosciences Ltd Anticorpos que reconhecem tau
IL312893A (en) 2019-03-18 2024-07-01 Regeneron Pharma Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation
US11155609B2 (en) 2019-04-05 2021-10-26 TauC3 Biologies Limited Anti-TAUC3 antibodies and uses thereof
WO2022144406A1 (en) 2020-12-29 2022-07-07 Neurimmune Ag Human anti-tau antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733734A (en) * 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
JPH06239899A (ja) 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US20020164657A1 (en) * 2001-02-23 2002-11-07 Sharma Satish K. Assays for assessing A beta-Tau aggregation

Also Published As

Publication number Publication date
RU2003126594A (ru) 2005-03-10
US20090123936A1 (en) 2009-05-14
AT500379B1 (de) 2009-07-15
CN100503638C (zh) 2009-06-24
WO2002062851A1 (en) 2002-08-15
AT500379B8 (de) 2009-08-15
ES2339427T3 (es) 2010-05-20
CA2437453C (en) 2013-06-11
JP4163955B2 (ja) 2008-10-08
US7446180B2 (en) 2008-11-04
CA2437453A1 (en) 2002-08-15
US20040082763A1 (en) 2004-04-29
JP2004532817A (ja) 2004-10-28
RU2299889C2 (ru) 2007-05-27
DE60235746D1 (de) 2010-05-06
EP1355949B1 (de) 2010-03-24
AT500379A2 (de) 2005-12-15
ATE461941T1 (de) 2010-04-15
AU2002237296A1 (en) 2002-08-19
CN101307107A (zh) 2008-11-19
EP1355949A1 (de) 2003-10-29
DK1355949T3 (da) 2010-05-25
CN1492879A (zh) 2004-04-28
WO2002062851A8 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
AT500379B1 (de) Tau-proteine
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
EP3569610A3 (de) Moleküle mit verlängerter halbwertzeit, zusammensetzungen und verwendungen dafür
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
EP2147928A3 (de) Auf Peptiden basierte Immunisierungstherapie zur Behandlung von Atherosklerose und Entwicklung von Peptid-basierten Assays zur Bestimmung von Immunreaktionen gegen oxidiertes Lipoprotein geringer Dichte
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
EP2267032A3 (de) Verfahren zur Verabreichung therapeutischer Polypeptide und Polypeptide dafür
EA200101250A1 (ru) Предупреждение и терапия амилоидогенного заболевания
DE602004011770D1 (de) Fusionsproteine
HUP0302589A2 (hu) A béta-amiloid peptidet felismerő humanizált ellenanyagok
EP2305286A3 (de) Behandlung von Alzheimerkrankheit
WO2000078344A8 (en) Prion protein peptides and uses thereof
EP1467757A4 (de) Verwendung von antikörpern gegen das muc18-antigen
DK2172208T3 (da) Små peptider til behandling af alzheimers sygdom og andre beta-amyloidprotein- fibrillogeneseforstyrrelser
EA200400134A1 (ru) Терапевтический агент
DE602006019582D1 (de) Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
AU2001232275A1 (en) Novel collagen-like protein clac, precursor thereof and genes encoding the same
ATE396203T1 (de) Auf peptiden basierende immunisierungstherapie zur behandlung von atheriosclerose
WO2001002429A3 (en) Angiopoietin-6 and uses thereof
WO2002046769A3 (en) A monoclonal antibody-based diagnostic assay for gamma fibrinogen

Legal Events

Date Code Title Description
PC Change of the owner

Owner name: AXON NEUROSCIENCE SE, CY

Effective date: 20191118

MK07 Expiry

Effective date: 20210202